Optimal fosamprenavir regimen to prevent lipid abnormalities

Emanuela Lattuada, Massimiliano Lanzafame, Carmela Grosso, Fabio Soldani, Fabiana Corsini, Silvia Storato, Sandro Vento

Research output: Contribution to journalArticle

Abstract

We report our experience on the impact of different fosamprenavir boosted regimens on plasma lipid levels in 48 naïve monoinfectd- HIV-seropositive patients. Eighteen months after starting antiretroviral therapy (ART), all patients showed a good immuno-virological response, with no statistically significant differences among the three groups; no changes in ART regimens were necessary and no adverse events were reported. On the contrary, a statistically significant difference among the three groups of patients was observed in cholesterol and triglyceride levels, since higher levels of cholesterol (including LDLs) and triglycerides were observed in patients taking the higher dose of ritonavir.

Original languageEnglish
Pages (from-to)200-202
Number of pages3
JournalActa Biomedica de l'Ateneo Parmense
Volume80
Issue number3
Publication statusPublished - Dec 1 2009

Keywords

  • Cholesterol level
  • Fosamprenavir
  • Ritonavir
  • Triglycerides levels

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Optimal fosamprenavir regimen to prevent lipid abnormalities'. Together they form a unique fingerprint.

  • Cite this

    Lattuada, E., Lanzafame, M., Grosso, C., Soldani, F., Corsini, F., Storato, S., & Vento, S. (2009). Optimal fosamprenavir regimen to prevent lipid abnormalities. Acta Biomedica de l'Ateneo Parmense, 80(3), 200-202.